TLR3 and COVID-19: Similarly, famotidine, a specific histamine H2 receptor antagonist, can inhibit TLR3 expression in SARS-CoV-2 infected cells and reduce TLR3-dependent NF-κB and IRF3 signaling, subsequently controlling antiviral and inflammatory responses (Mukherjee et al., 2021) and reducing the risk of intubation and death in hospitalized patients with COVID-19 (Freedberg et al., 2020).